Lv7
3320 积分 2021-12-27 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development
1个月前
已完结
Advances in Locoregional and Systemic Treatments for HCC
3个月前
已完结
A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
3个月前
已完结
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
4个月前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
6个月前
已完结
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
6个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
8个月前
已完结
[Expert consensus on the diagnosis and treatment of esophageal and gastric variceal rupture bleeding in cirrhotic portal hypertension (2024 edition)]
8个月前
已完结
皖公网安备34019202002308
